CorAssist Cardiovascular - Innovative Solutions for heart failure with preserved ejection fraction (HFpEF)
Over 5.7 million people in the US
and 20 million people worldwide
suffer from heart failure.
CorAssist Cardiovascular - Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

Company Profile

CorAssist is a clinical stage medical device company committed to developing innovative therapeutic products for treating Heart Failure with Preserved Ejection Fraction. The company's proprietary technology enables the first implantation of a device that directly improves cardiac diastolic function.

The company's product, the CORolla®, is an elastic self-expanding internal spring-like device implanted inside the left ventricular, through a Transapical or percutaneous procedure. The device assists diastolic function by improving diastolic dynamics and filling performance, and does not require an external power source.

The company has completed pre-clinical studies, proving the safety of the CORolla®, and has initiated its First in Man clinical study during 2013.

The company’s ImCardia® first product is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off pump procedure. The company succeeded in presenting safety and demonstrated efficacy parameters in two years follow-up clinical study, in which the device was implanted in humans, thereby showing the proof of concept of the device.

CorAssist was founded in 2003 by a group of three physicians, Dr. Yair Feld, Dr. Yotam Reisner and Dr. Shay Dubi, and is privately held by its investors and employees.